Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies.
Authors
Cooney, Marie-ThereseDudina, Alexandra
Whincup, Peter
Capewell, Simon
Menotti, Alessandro
Jousilahti, Pekka
Njølstad, Inger
Oganov, Raphel
Thomsen, Troels
Tverdal, Aage
Wedel, Hans
Wilhelmsen, Lars
Graham, Ian
Affiliation
Department of Cardiology, Adelaide Meath Hospital, Tallaght, Dublin, Ireland.Issue Date
2009-10MeSH
AdultAged
Aged, 80 and over
Antihypertensive Agents
Aspirin
Biological Markers
Blood Pressure
Cardiovascular Diseases
Cholesterol
Cohort Studies
Europe
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Mass Screening
Middle Aged
Patient Compliance
Population Surveillance
Preventive Health Services
Risk Assessment
Risk Factors
Risk Reduction Behavior
Smoking
Smoking Cessation
Time Factors
Treatment Outcome
Young Adult
Metadata
Show full item recordCitation
Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. 2009, 16 (5):541-9 Eur J Cardiovasc Prev RehabilJournal
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise PhysiologyDOI
10.1097/HJR.0b013e32832b38a1PubMed ID
19773660Abstract
Options for the prevention of cardiovascular disease, the greatest global cause of death, include population preventive measures (the Rose approach), or specifically seeking out and managing high-risk cases. However, the likely benefit of a population approach has been recently questioned.Item Type
ArticleLanguage
enISSN
1741-8275ae974a485f413a2113503eed53cd6c53
10.1097/HJR.0b013e32832b38a1
Scopus Count
Collections
Related articles
- Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
- Authors: Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Rodgers A
- Issue date: 2014 Feb
- Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
- Authors: Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, Patel A, Prabhakaran D, Webster R, Thom S, Rodgers A, UMPIRE investigators
- Issue date: 2017 Jun
- A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
- Authors: Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A, Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration
- Issue date: 2015 Jul
- Changes in preventive medical therapies and CV risk factors after CT angiography.
- Authors: Cheezum MK, Hulten EA, Smith RM, Taylor AJ, Kircher J, Surry L, York M, Villines TC
- Issue date: 2013 May
- Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
- Authors: Lafeber M, Webster R, Visseren FLj, Bots ML, Grobbee DE, Spiering W, Rodgers A, Programme to Improve Life and Longevity (PILL) Collaborative Group
- Issue date: 2016 Aug